Sign in or create an account to add this stock to your watchlist.
About Enanta Pharmaceuticals (NASDAQ:ENTA)
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800
Debt
Debt-to-Equity RatioN/A
Current Ratio17.86
Quick Ratio17.86
Price-To-Earnings
Trailing P/E Ratio110.68
Forward P/E Ratio31.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$102.81 million
Price / Sales18.81
Cash Flow$1.0341 per share
Price / Cash97.04
Book Value$15.80 per share
Price / Book6.35
Profitability
EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins31.60%
Return on Equity18.50%
Return on Assets17.30%
Miscellaneous
Employees89
Outstanding Shares19,270,000
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals (NASDAQ:ENTA) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.53 by $0.08. The biotechnology company earned $44 million during the quarter, compared to analysts' expectations of $40.77 million. Enanta Pharmaceuticals had a net margin of 31.60% and a return on equity of 18.50%. The business's revenue for the quarter was up 388.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.28) EPS. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
What price target have analysts set for ENTA?
4 analysts have issued 1 year price objectives for Enanta Pharmaceuticals' shares. Their predictions range from $36.00 to $80.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $51.75 in the next year. View Analyst Ratings for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH) and FibroGen (FGEN).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
- Mr. Paul J. Mellett Jr., Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer (Age 63)
- Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
- Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)
Has Enanta Pharmaceuticals been receiving favorable news coverage?
Media coverage about ENTA stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.27 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Enanta Pharmaceuticals' major shareholders?
Enanta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.34%), Farallon Capital Management LLC (4.75%), Dimensional Fund Advisors LP (3.10%), Franklin Resources Inc. (1.49%), Matarin Capital Management LLC (1.17%) and Prudential Financial Inc. (1.13%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Which major investors are selling Enanta Pharmaceuticals stock?
ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Franklin Resources Inc., Barclays PLC, Virginia Retirement Systems ET AL, Farallon Capital Management LLC and Northern Trust Corp. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda and Paul J Mellett. View Insider Buying and Selling for Enanta Pharmaceuticals.
Which major investors are buying Enanta Pharmaceuticals stock?
ENTA stock was bought by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Prudential Financial Inc., Spark Investment Management LLC, California Public Employees Retirement System, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, UBS Group AG and Russell Investments Group Ltd.. View Insider Buying and Selling for Enanta Pharmaceuticals.
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $100.35.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $2.01 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Enanta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.75, suggesting that the stock has a possible downside of 48.43%. The high price target for ENTA is $80.00 and the low price target for ENTA is $36.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Buy |
| Consensus Rating Score: | 2.25 | 2.25 | 2.25 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.75 | $51.75 | $51.25 | $46.25 |
| Price Target Upside: | 48.43% downside | 38.44% downside | 42.45% downside | 6.96% downside |
Enanta Pharmaceuticals (NASDAQ:ENTA) Consensus Price Target History
Enanta Pharmaceuticals (NASDAQ:ENTA) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Enanta Pharmaceuticals (NASDAQ:ENTA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.56%
Institutional Ownership Percentage: 76.05%
Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Jay R Luly | Insider | Sell | 25,000 | $105.83 | $2,645,750.00 | 638,994 |  |
| 5/16/2018 | Nathalie Adda | VP | Sell | 4,155 | $105.25 | $437,313.75 | 8,955 | |
| 4/16/2018 | Nathalie Adda | VP | Sell | 4,225 | $85.58 | $361,575.50 | 10,225 | |
| 3/19/2018 | Paul J Mellett | Treasurer | Sell | 9,000 | $86.48 | $778,320.00 | 96,458 | |
| 1/4/2017 | Yat Sun Or | Insider | Sell | 13,921 | $35.09 | $488,487.89 | 301,876 | |
| 11/29/2016 | Yat Sun Or | Insider | Sell | 13,921 | $31.44 | $437,676.24 | 315,797 | |
| 5/11/2016 | Nathaniel S Gardiner | VP | Buy | 500 | $24.45 | $12,225.00 | 1,900 | |
| 2/12/2016 | Terry Vance | Director | Buy | 2,000 | $27.04 | $54,080.00 | 15,295 | |
| 11/24/2015 | Paul J. Mellett | CFO | Sell | 6,000 | $30.15 | $180,900.00 | 54,397 | |
| 10/15/2015 | Paul J Mellett | CFO | Sell | 7,500 | $40.10 | $300,750.00 | 60,397 | |
| 9/8/2015 | Paul J. Mellett | CFO | Sell | 7,500 | $39.55 | $296,625.00 | 67,897 | |
| 7/13/2015 | Paul J Mellett | CFO | Sell | 7,500 | $46.29 | $347,175.00 | | |
| 7/13/2015 | Yat Sun Or | Insider | Sell | 3,750 | $46.29 | $173,587.50 | | |
| 6/11/2015 | Paul J Mellett | CFO | Sell | 7,500 | $42.51 | $318,825.00 | | |
| 6/11/2015 | Yat Sun Or | Insider | Sell | 3,750 | $42.47 | $159,262.50 | | |
| 6/5/2015 | Yat Sun Or | Insider | Sell | 10,750 | $42.02 | $451,715.00 | | |
| 5/19/2015 | Paul J Mellett | CFO | Sell | 24,000 | $40.13 | $963,120.00 | | |
| 5/11/2015 | Yat Sun Or | Insider | Sell | 8,000 | $36.13 | $289,040.00 | | |
| 3/9/2015 | Jay R Luly | CEO | Sell | 15,000 | $33.37 | $500,550.00 | | |
| 2/20/2015 | Jay R Luly | CEO | Sell | 15,000 | $35.35 | $530,250.00 | | |
| 2/19/2015 | Stephen Jr. Buckley | Director | Buy | 1,000 | $34.00 | $34,000.00 | | |
| 2/17/2015 | Nathaniel S Gardiner | VP | Buy | 1,400 | $33.23 | $46,522.00 | | |
| 1/16/2015 | Paul J Mellett | CFO | Sell | 4,500 | $49.45 | $222,525.00 | | |
| 1/5/2015 | Jay R Luly | CEO | Sell | 15,000 | $50.43 | $756,450.00 | | |
| 12/1/2014 | Jay R Luly | CEO | Sell | 15,000 | $45.39 | $680,850.00 | | |
| 11/3/2014 | Jay R Luly | CEO | Sell | 15,000 | $42.52 | $637,800.00 | | |
| 9/15/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.83 | $398,300.00 | | |
| 8/14/2014 | Paul J Mellett | CFO | Sell | 10,000 | $39.13 | $391,300.00 | | |
| 8/14/2014 | Stephen Jr. Buckley | Director | Buy | 1,000 | $38.95 | $38,950.00 | | |
| 7/14/2014 | Paul J Mellett | CFO | Sell | 20,000 | $39.88 | $797,600.00 | | |
| 5/1/2014 | Yat Sun Or | Insider | Sell | 5,000 | $36.98 | $184,900.00 | 184,078 | |
| 4/1/2014 | Jay Luly | CEO | Sell | 15,000 | $39.17 | $587,550.00 | 544,338 | |
| 4/1/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.16 | $391,600.00 | 189,078 | |
| 3/24/2014 | Yat Sun Or | Insider | Sell | 10,000 | $39.34 | $393,400.00 | 199,078 | |
| 3/4/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 439,334 | $38.82 | $17,054,945.88 | | |
| 2/26/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 230,190 | $39.15 | $9,011,938.50 | | |
| 2/24/2014 | V Life Science Ventures Gm Tvm | major shareholder | Sell | 60,477 | $39.57 | $2,393,074.89 | | |
| 2/14/2014 | Jay Luly | CEO | Sell | 5,800 | $38.10 | $220,980.00 | 569,338 | |
| 1/2/2014 | Jay R Luly | CEO | Sell | 5,800 | $28.05 | $162,690.00 | | |
| 12/6/2013 | Marc E Goldberg | Director | Sell | 6,861 | $27.93 | $191,627.73 | | |
| 10/14/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 32,301 | $19.84 | $640,851.84 | | |
| 10/10/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 36,207 | $21.71 | $786,053.97 | | |
| 10/3/2013 | Saints Capital Granite, L.P. | Major Shareholder | Sell | 12,300 | $23.39 | $287,697.00 | | |
| 3/26/2013 | Helmut Schuhsler | Director | Buy | 132,949 | $14.00 | $1,861,286.00 | | |
| 3/26/2013 | Saints Capital Granite, L.P. | Major Shareholder | Buy | 66,474 | $14.00 | $930,636.00 | | |
(Data available from 1/1/2013 forward)
Enanta Pharmaceuticals (NASDAQ ENTA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Nathalie Adda Sells 4,155 Shares of Enanta Pharmaceuticals (ENTA) Stock
www.americanbankingnews.com - May 18 at 7:52 PM |
| Jay R. Luly Sells 25,000 Shares of Enanta Pharmaceuticals (ENTA) Stock
www.americanbankingnews.com - May 18 at 7:27 PM |
 | Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study
finance.yahoo.com - May 18 at 5:05 PM |
| Zacks: Brokerages Anticipate Enanta Pharmaceuticals (ENTA) Will Announce Quarterly Sales of $55.97 Million
www.americanbankingnews.com - May 18 at 5:00 AM |
| Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.87 Per Share
www.americanbankingnews.com - May 16 at 5:21 AM |
| Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
finance.yahoo.com - May 10 at 5:06 PM |
| Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses
finance.yahoo.com - May 10 at 5:06 PM |
| Enanta Pharmaceuticals (ENTA) Issues Earnings Results
www.americanbankingnews.com - May 9 at 6:35 PM |
 | BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61
www.reuters.com - May 9 at 4:54 PM |
| Edited Transcript of ENTA earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 9 at 4:54 PM |
 | Enanta Pharmaceuticals' (ENTA) CEO Jay Luly on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:04 AM |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018
finance.yahoo.com - May 8 at 4:54 PM |
| Enanta Pharmaceuticals: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 8 at 4:54 PM |
| Calculating The Intrinsic Value Of Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
finance.yahoo.com - May 8 at 8:58 AM |
| Enanta Pharmaceuticals (ENTA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 11:38 AM |
 | Notable Friday Option Activity: BG, PEGI, ENTA
www.nasdaq.com - May 4 at 4:48 PM |
| Enanta Pharmaceuticals (ENTA) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - May 3 at 11:46 PM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals (ENTA) Will Post Quarterly Sales of $30.01 Million
www.americanbankingnews.com - April 30 at 2:42 AM |
| Enanta Pharmaceuticals (ENTA) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 2:38 AM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals (ENTA) Will Post Earnings of $0.10 Per Share
www.americanbankingnews.com - April 28 at 3:12 PM |
 | Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 pm ET to Discuss Financial Results for its Fiscal ...
www.businesswire.com - April 26 at 8:52 AM |
| Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2018
finance.yahoo.com - April 24 at 8:58 AM |
| Enanta Pharmaceuticals (ENTA) Upgraded at JMP Securities
www.americanbankingnews.com - April 19 at 4:00 PM |
| Enanta Pharmaceuticals (ENTA) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 19 at 1:56 PM |
| Enanta Pharmaceuticals (ENTA) VP Nathalie Adda Sells 4,225 Shares
www.americanbankingnews.com - April 18 at 7:29 PM |
| Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH
finance.yahoo.com - April 16 at 8:55 AM |
| $30.01 Million in Sales Expected for Enanta Pharmaceuticals (ENTA) This Quarter
www.americanbankingnews.com - April 13 at 2:21 AM |
| Robert W. Baird Boosts Enanta Pharmaceuticals (ENTA) Price Target to $36.00
www.americanbankingnews.com - April 12 at 8:29 PM |
| Enanta Pharmaceuticals (ENTA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 11:47 AM |
| Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - April 11 at 5:18 PM |
| Enanta Pharmaceuticals (ENTA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 10 at 11:04 PM |
| Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session
finance.yahoo.com - April 5 at 11:05 AM |
| Bio-Path Leukemia Combo Study Shows Positive Early Data
finance.yahoo.com - April 4 at 3:39 PM |
| Enanta Pharmaceuticals (ENTA) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 4 at 11:42 AM |
| Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - April 4 at 9:05 AM |
| Enanta Pharmaceuticals (ENTA) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM |
| Enanta Pharmaceuticals (ENTA) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:49 PM |
 | Enanta Pharma (ENTA) Announces Data Presentations at The International Liver Congress
www.streetinsider.com - March 28 at 4:47 PM |
 | Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018
www.finanznachrichten.de - March 28 at 9:14 AM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 27 at 3:40 AM |
| Zacks: Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - March 25 at 7:12 PM |
| Enanta Pharmaceuticals Inc (ENTA) Treasurer Paul J. Mellett Sells 9,000 Shares
www.americanbankingnews.com - March 20 at 7:34 PM |
| Enanta Pharmaceuticals Inc (ENTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 11:40 AM |
| Enanta Pharmaceuticals (ENTA) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 14 at 7:50 PM |
| Enanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 10 at 6:06 AM |
| Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.10 EPS
www.americanbankingnews.com - March 8 at 1:36 PM |
| Bristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
finance.yahoo.com - March 8 at 9:13 AM |
| Annual HC Wainwright NASH Investor Conference - Business Wire (press release)
www.businesswire.com - March 7 at 5:43 PM |
| Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
finance.yahoo.com - March 6 at 5:08 PM |
| Enanta Pharmaceuticals Inc (ENTA) Holdings Reduced by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 9:58 AM |
Enanta Pharmaceuticals (NASDAQ:ENTA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Enanta Pharmaceuticals (NASDAQ:ENTA) Income Statement, Balance Sheet and Cash Flow Statement
Enanta Pharmaceuticals (NASDAQ ENTA) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
